The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy

Table 1

Patient characteristics.

	Number of patients	Percentage or range
Mean years of age at diagnosis	56.4	32–77
Menopausal status	53	100
Premenopausal	17	32.1
Postmenopausal	28	52.8
Not known	8	15.1
Bilateral breast cancer	53	100
Bilateral breast cancer	4	7.5
Unilateral breast cancer	49	92.5
NACT received	53	100
Docetaxel + doxorubicin	20	37.7
Docetaxel + trastuzumab	14	26.4
Docetaxel + epirubicin	3	5.7
Other chemotherapy	16	30.2
Median number of neoadjuvant cycles	6.0	2–16
Surgical procedure	53	100
Mastectomy and axillary evacuation	53	100
Adjuvant chemotherapy	53	100
Cyclophosphamide + epirubicin + fluorouracil	11	20.8
Other chemotherapy	18	34
No adjuvant chemotherapy	24	45.3
Radiotherapy	53	100
Yes	52	98.1
No	1	1.9
Adjuvant endocrine therapy	53	100
Tamoxifen	10	18.9
Aromatase inhibitor	23	43.4
GnRH analogue + tamoxifen	5	9.4
GnRH analogue + aromatase inhibitor	1	1.9
Tamoxifen and aromatase inhibitor (sequentially)	2	3.8
No adjuvant hormonal therapy	12	22.6
Recurrence status	53	100
Distant	20	37.7
Local	3	5.6
No recurrence	30	56.6